Updated Kaplan-Meier estimates of overall survival (OS) of our previously reported cohort of 282 higher-risk myelodysplastic syndromes (MDS) patients treated with azacitidine, with a median follow-up of 41.3 months. (A) Global cohort (n = 282).¹  (B) Cohort according to our risk stratification: low (n = 30, median OS: 32.1 month); intermediate (int; n = 191, median OS: 15.0 months); high (n = 48; median OS: 6.1 month; log-rank test: P < 10⁻⁴).